fda glp-1 compounding warning october 2025 September 8, 2025: FDA launches an import alert listing safe GLP-1 manufacturers – Partnership for Safe Medicines

FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading

21.14

★★★★☆4.8 (126)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

22.99

★★★★★4.9 (98)

GLP-1 compounding is facing increased scrutiny, and the path forward is far from clear. ㅤ Recent FDA messaging has raised questions across the industry, with potential enforcement around GLP-1 APIs creating uncertainty

29.92

★★★★★5.0 (157)

Congress Introduces SAFE Drugs Act of 2025, Expanding FDA Oversight of Compounded GLP-1 Drugs and Telehealth Providers

29.59

★★★★★4.7 (84)

September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns FDA – Partnership for Safe Medicines

20.49

★★★★★4.9 (203)

Out of Shortage, Into Controversy: The Fight Over GLP-1 Compounding

21.38

★★★★★5.0 (176)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

27.52

★★★★★4.8 (132)